AR096848A1 - Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) - Google Patents

Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)

Info

Publication number
AR096848A1
AR096848A1 ARP140102528A ARP140102528A AR096848A1 AR 096848 A1 AR096848 A1 AR 096848A1 AR P140102528 A ARP140102528 A AR P140102528A AR P140102528 A ARP140102528 A AR P140102528A AR 096848 A1 AR096848 A1 AR 096848A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
independently
hydrogen atom
ring
Prior art date
Application number
ARP140102528A
Other languages
English (en)
Inventor
Aida Jumpei
Takahashi Masashi
Kakegawa Keiko
Ikoma Minoru
Igawa Hideyuki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR096848A1 publication Critical patent/AR096848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporciona un compuesto que tiene una acción antagonista del receptor de la hormona concentradora de melanina y que es útil como agente para la profilaxis o el tratamiento de la obesidad y similares. Reivindicación 1: Un compuesto representado por la fórmula (1), caracterizado porque el anillo Ar es un anillo aromático además sustituido en forma opcional; L¹ es O, S(O)ₘ₁, NR³A o CR³BR³C; L² es O, S(O)ₘ₂, NR⁴A o CR⁴BR⁴C; (con la exclusión de la combinación en que L¹ sea distinto de CR³BR³C y L² sea distinto de CR⁴BR⁴C); m1 y m2 son cada uno en forma independiente un número entero de 0 a 2; R³A y R⁴A son cada uno en forma independiente un átomo de hidrógeno o un grupo hidrocarburo sustituido en forma opcional; R³B, R³C, R⁴B y R⁴C son cada uno en forma independiente un átomo de hidrógeno o un sustituyente; cuando L¹ es CR³BR³C y el anillo Ar tiene sustituyente(s), R³B y el sustituyente se encuentran unidos en forma opcional entre sí para formar un anillo sustituido en forma opcional; X¹, X² y X³ son cada uno en forma independiente CR⁵ o N; R⁵ es un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; R¹ es un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; R² es un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; Y¹, Y² e Y³ son cada uno en forma independiente CR⁶ o N; y R⁶ es un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; o una sal del mismo.
ARP140102528A 2013-07-09 2014-07-08 Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) AR096848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013143940 2013-07-09

Publications (1)

Publication Number Publication Date
AR096848A1 true AR096848A1 (es) 2016-02-03

Family

ID=51220851

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102528A AR096848A1 (es) 2013-07-09 2014-07-08 Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)

Country Status (9)

Country Link
US (1) US9199963B2 (es)
EP (1) EP3019487A1 (es)
JP (1) JP2016523809A (es)
CN (1) CN105358544A (es)
AR (1) AR096848A1 (es)
CA (1) CA2917490A1 (es)
TW (1) TW201536767A (es)
UY (1) UY35650A (es)
WO (1) WO2015005489A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365540B2 (en) * 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists
EP2848621A4 (en) * 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC CYCLIC COMPOUND
JP2023506917A (ja) 2019-12-20 2023-02-20 バイエル・アクチエンゲゼルシヤフト 置換チオフェンカルボキサミド、チオフェンカルボン酸およびその誘導体
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
CA2302992C (en) 1997-09-05 2011-11-01 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
EP1042498A4 (en) 1997-12-03 2003-05-07 Smithkline Beecham Corp METHOD FOR SEARCHING FOR AN AGONIST OR ANTAGONIST OF THE HUMAN 11 CB SPLICE VARIANT
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2407149C (en) 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
JP2005523237A (ja) 2001-10-01 2005-08-04 大正製薬株式会社 Ｍｃｈ受容体アンタゴニスト
US7101845B2 (en) 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
US20060183789A1 (en) 2002-09-25 2006-08-17 Lavanya Rajachandran Methods for preventing and treating obesity in patients with mc4 receptor mutations
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005040824A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20100184648A1 (en) 2005-03-29 2010-07-22 Akira Gomori Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
EP2431367A3 (en) 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
WO2008047821A1 (fr) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
GEP20115241B (en) 2006-10-19 2011-06-10 Takeda Pharmaceutical Indole compound
AU2007329480A1 (en) 2006-12-05 2008-06-12 National Chio Tung University Indazole compounds
CN101687879B (zh) 2007-01-10 2013-01-02 阿尔巴尼分子研究公司 5-呋喃并吡啶酮取代的吲唑
MX2009007337A (es) * 2007-01-10 2009-07-15 Albany Molecular Res Inc Indazoles sustituidos con 5-piridinona.
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
TW200838515A (en) 2007-02-09 2008-10-01 Takeda Pharmaceutical Fused ring compound
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2011127643A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2011130086A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
US9365540B2 (en) * 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists

Also Published As

Publication number Publication date
US9199963B2 (en) 2015-12-01
UY35650A (es) 2015-02-27
JP2016523809A (ja) 2016-08-12
US20150018373A1 (en) 2015-01-15
EP3019487A1 (en) 2016-05-18
CA2917490A1 (en) 2015-01-15
CN105358544A (zh) 2016-02-24
WO2015005489A1 (en) 2015-01-15
TW201536767A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
SV2017005472A (es) Compuestos de triazolopirimidina y usos de los mismos
AR110038A1 (es) Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CR20160098A (es) Polimorfo de los inhibidores de la syk
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
MX362582B (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
EA201692219A1 (ru) Способы получения противовирусных соединений
AR097866A1 (es) Derivados de 4-azaindol
AR089527A1 (es) Inhibidores de bromodominios
AR106138A1 (es) Compuestos y métodos para inhibir jak
AR111983A1 (es) ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR096848A1 (es) Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR090836A1 (es) Derivados de benzamida
AR103232A1 (es) ANTAGONISTAS DE TGFbR
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)
AR093057A1 (es) Inhibidores de la syk
CU24248B1 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato como antagonistas del receptor-h3
AR100439A1 (es) Derivados de carboxamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure